XOMA Corporation
http://www.xoma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XOMA Corporation
Glenmark Chief: Running A Facility In The US Has Been A Struggle
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.
Outlook Pulls Bevacizumab BLA As Filing Falls Short
Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.
Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Torrent Acquires Chronic Brands From Dr Reddy’s, Folds Up US Liquids Business
Torrent is recalibrating strategy with the addition of chronic therapies from Dr Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.
Company Information
- Industry
- Miscellaneous
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Enumeral Biomedical Inc.
- XOMA Ltd.